ProCE Banner Activity

Key HIV Studies Influencing My Practice Following AIDS 2022

Slideset Download
Conference Coverage

Read expert faculty members’ summaries of key HIV studies from AIDS 2022, including results from studies of prevention strategies, oral therapies, long-acting therapies, cure, and comorbidities.

Released: August 17, 2022

Expiration: August 16, 2023

Share

Faculty

Chloe Orkin

Chloe Orkin, MBChB, FRCP, MD

Professor of Infection and Inequities
Dean for Healthcare Transformation
Queen Mary University of London
Faculty of Medicine and Dentistry
London, United Kingdom

Babafemi Taiwo

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

David A. Wohl

David A. Wohl, MD

Professor of Medicine
School of Medicine
Site Leader, Global Clinical Trials Unit-Chapel Hill
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

ViiV Healthcare

Partners

IAS 2021

ProCE Banner

Faculty Disclosure

Primary Author

Chloe Orkin, MBChB, FRCP, MD

Professor of Infection and Inequities
Dean for Healthcare Transformation
Queen Mary University of London
Faculty of Medicine and Dentistry
London, United Kingdom

Chloe Orkin, MBChB, FRCP, MD: consultant/advisor/speaker: Gilead, GlaxoSmithKline, Merck Sharp & Dohme, ViiV.

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

David A. Wohl, MD

Professor of Medicine
School of Medicine
Site Leader, Global Clinical Trials Unit-Chapel Hill
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

David A. Wohl, MD: consultant/advisor/speaker: EMD Serono, Gilead, Janssen, Merck, Theratechnologies, ViiV.